The Filing Desk

Rockwell Medical vs Spero Therapeutics

Rockwell Medical RMTI · Spero Therapeutics SPRO · Pharmaceuticals

Rockwell Medical reported revenue of $69 million in fiscal 2025, about the same as Spero Therapeutics' $67 million in fiscal 2025. Rockwell Medical's revenue fell 31.8% in its latest year, and Spero Therapeutics' grew 39.2%. Rockwell Medical had an operating margin of -6.8%, against 9.4% at Spero Therapeutics.

Side by side

Rockwell MedicalSpero Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$69M$67M
Revenue growth−31.8%39.2%
Revenue growth a year, last 5 years2.2%48.3%
Gross margin16.9%—
Operating margin−6.8%9.4%
Net margin−7.7%12.8%
Free cash flow−$1M—
Free cash flow margin−1.7%—
Return on capital−17.4%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count15.8%9.3%
Last close$6.26$0.83
P/E at the last close——
Insider trades, last 12 monthssold $3,153sold $456,601
Piotroski F-score3 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Rockwell MedicalSpero Therapeutics
Operating margin
Percent of revenue
Rockwell MedicalSpero Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Rockwell MedicalSpero Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Rockwell Medical and Spero Therapeutics pages.